

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

Neha Bhagwat, PhD

Associate Professor & Treatment

[Learn About Cancer & Treatment](#)

Director, Translational Medicine at Prelude Therapeutics Inc., Wilmington,

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)


[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Dissertation

[JAK2 is a Therapeutic Target in Myeloproliferative Neoplasms \(2014\)](#)

Mentor

[Ross L. Levine, MD](#)

Start Year

2008

End Year

2014

Education

Drexel University

Publications

[Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL. \(2015\) JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. *Cancer discovery*, 5, 316-31. PMID: PMC4355105.](#)

[Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Teruya-Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Armstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe . \(2015\) Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. *Blood*, 126, 2479-83. PMID: PMC4661170.](#)

[Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V. \(2014\) Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. *Leukemia*, 28, 1918-22. PMID: PMC4158830.](#)

[Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, Bhagwat N, Marubayashi S, Levine RL. \(2014\) Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. *Blood*, 124, 2280-4. PMID: PMC4183987.](#)

[Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel H, Shah S, Taldone T, Bradner J, Chiosis G, Levine R. \(2014\) Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. *Blood*, 123, 2075-2083.](#)

[Murphy A, Bijl N, Yvan-Charvet L, Welch C, Bhagwat N, Reheman A, Wang Y, Shaw J, Levine R, Ni H, Tall A, Wang N. \(2013\) Cholesterol efflux in megakaryocyte progenitors suppresses platelet production](#)

[and thrombocytosis. *Nat Med*, 19, 586-594.](#)

[Gautier E, Westerterp M, Bhagwat N, Cremers S, Shih A, Abdel-Wahab O, Lütjohann D, Randolph G, Levine R, Tall A, Tvan-Charvet L. \(2013\) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. *J Exp Med*, 210, 339-353.](#)

[Bhagwat N, Levine R, Koppikar P. \(2013\) Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. *Int J Hematol*, 97, 695-702.](#)

[Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders L, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert B, Chiosis G, Nimer S, Bernstein B, Verstovsek S, Levine R. \(2012\) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. *Nature*, 489, 155-159.](#)

[Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, Marque F, Régnier C, De Pover A, Ryckelynck H, Bhagwat N, Koppikar P, Goel A, Wyder L, Tavares G, Baffert F, Pissot-Soldermann C, Manley P, Gaul C, Voshol H, Levine R, Sellers W, Hofmann F, Radimerski T. \(2012\) Modulation of activation-loop phosphorylation by JAK inhibitors is binding more dependent. *Cancer Discov*, 2, 512-523.](#)

[Marubayashi S, Koppikar P, Taydone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes R, Ross K, Gönen M, Gozman A, Ahn, J, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner J, Chiosis G, Levine R. \(2010\) HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. *J Clin Invest*, 120, 3578-3593.](#)

[Figuerola M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez H, Tallman M, Sun Z, Wolniak K, Peeters J, Liu W, Chloe S, Fantin V, Paietta E, Löwenberg B, Licht J, Godley L, Delwel R, Valk P, Thompson C, Levine R, Melnick A. \(2010\) Leukemia IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*, 18, 553-567.](#)

[Bhagwat N, Levine R. \(2010\) Metabolic syndromes and malignant transformation: where the twain shall meet. *Sci Transl Med*, 2, 1-3.](#)

[View a full listing of Neha Bhagwat's journal articles.](#)

